What is AnaCardio?
AnaCardio AB is a privately held Swedish biopharmaceutical company operating at the clinical stage of drug development. The company is focused on creating novel therapeutics for heart failure, leveraging groundbreaking research from Karolinska Institutet. Their lead program, AC01, is an oral ghrelin peptidomimetic small-molecule designed to enhance heart muscle contractility. This differentiated mechanism aims to address a critical unmet need in cardiovascular medicine, positioning AnaCardio as a key player in the biopharma landscape.
How much funding has AnaCardio raised?
AnaCardio has raised a total of $56.2M across 2 funding rounds:
Series A
$19M
Series A
$37.2M
Series A (2024): $19M with participation from Flerie Invest, Industrifonden, and Karolinska Development
Series A (2025): $37.2M led by Sound Bioventures, Karolinska Development, Novo Holdings, Pureos Bioventures, Flerie Invest, and Industrifonden
Key Investors in AnaCardio
Sound Bioventures
Sound Bioventures is a venture capital fund that invests in clinical and about-to-be clinical stage private companies in Europe and the USA, focusing on the development of novel medicines for significant unmet medical needs.
Karolinska Development
Karolinska Development AB is a company that operates in the Insurance industry. It employs 100to249 people and has 10Mto25M of revenue. The company is headquartered in Sweden.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
What's next for AnaCardio?
With the recent substantial backing, AnaCardio is poised for accelerated growth and the advancement of its AC01 program through critical clinical trials. The strategic investment signals a strong belief in the company's scientific foundation and therapeutic potential. Future developments will likely focus on expanding the clinical pipeline, potentially exploring additional indications for AC01, and preparing for later-stage development and commercialization. This funding round is expected to enable AnaCardio to achieve key milestones, further solidifying its position in the competitive heart failure market.
See full AnaCardio company page
